Protective effects of lactococci strains delivering either IL-10 protein or cdna in a tnbs-induced chronic colitis model

MARTIN, R.; DEL CARMEN, S.; SARAIVA, T.; ZURITA-TURK, M.; MIYOSHI, A.; AZEVEDO, V.; LANGELLA, P.; BERMUDEZ-HUMARAN, L.; DE MORENO DE LEBLANC, A.; LEBLANC, JEAN GUY

Oviedo

Workshop; VI Workshop Probióticos, Prebióticos y Salud: Evidencia Científica; 2015

Sociedad Española de probioticos y prebioticos

Oral treatment with Lactococcus (L.) lactis strains secreting the anti-inflammatory cytokine IL-10 has previously shown success as a therapy for inflammatory bowel diseases (IBD). Our aim was to compare the protective effects of IL-10, delivered by recombinant lactoccoci using two novel expression systems, in a murine colitis model mimicking the relapsing nature of IBD. The first system is based on a Stress-Inducible Controlled Expression (SICE) system for the production and delivery of heterologous proteins at mucosal surfaces and the second allows the delivery to the host cells of an il-10 cDNA cassette, harbored in a eukaryotic DNA expression vector (pValac). Colitis was induced in female BALB/c mice by intrarectal injection of 2,4,6-trinitrobenzenesulphonic acid (TNBS). Mice that recovered received one of the bacteria treatments or saline solution orally during 14 days. Colitis was reactivated 25 days after the first TNBS injection with a second TNBS challenge. Three days after colitis reactivation, cytokine profiles and inflammation in colon samples were evaluated. Animals (N=9) receiving L. lactis strains secreting IL-10 using SICE system or delivering pValac:il-10 plasmid showed lower weight loss (p